Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BL-M07D1

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biokin Pharma

Drug class:

Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate

Related drugs:

‹

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

ado-trastuzumab emtansine (97)

disitamab vedotin (27)

trastuzumab duocarmazine (6)

PF-06804103 (4)

MF-TTZ-MMAE (1)

›

HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2